Robin LaChapelle - Feb 3, 2025 Form 4 Insider Report for ArriVent BioPharma, Inc. (AVBP)

Role
Chief Operating Officer
Signature
/s/ James Kastenmayer, Attorney-in-Fact for Robin LaChapelle
Stock symbol
AVBP
Transactions as of
Feb 3, 2025
Transactions value $
$0
Form type
4
Date filed
2/14/2025, 04:25 PM
Previous filing
Sep 23, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVBP Stock Option (right to buy) Award $0 +120K $0.00 120K Feb 3, 2025 Common Stock 120K $27.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest as to 25% on February 3, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.